What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
25位分析師對再生元製藥公司的看法
A clear picture of Regeneron...25 analysts have shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN) during the recent three months, expressing a mix of bullish and bearish perspectives.
在最近三個月中，25位分析師對再生元製藥公司（納斯達克：REGN）進行了評估，表達了看好和看淡的觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們近期評級的彙總視圖，展示了過去30天的情緒變化，並將其與前幾個月進行了比較。
Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $1086.64, a high estimate of $1300.00, and a low estimate of $165.00. A 10.22% drop is evident in the current average compared to the previous average price target of $1210.38.
分析師爲再生元製藥公司設定了12個月的價格目標，揭示出平均目標爲1086.64美元，最高預估爲1300.00美元，最低預估爲165.00美元。當前平均價格相比於之前的平均目標1210.38美元顯現出10.22%的下跌。
Deciphering Analyst Ratings: An In-Depth Analysis
分析師評級解讀：深入分析
A clear picture of Regeneron...
通過對最近...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間